Eli Lilly's CEO Says This Could Be a Game Changer for Its Business

Eli Lilly (NYSE: LLY) is a leading healthcare company that has been generating some incredible results in recent years. It has some excellent GLP-1 drugs in its portfolio -- Zepbound and Mounjaro -- which are in high demand from patients looking to lose weight and become healthier. The knock on the stock these days, however, is that it may have gotten too expensive, and that demand may also slow down in the future. As a result, shares of Eli Lilly haven't been all that hot of late. Instead, they've been in ...